153 related articles for article (PubMed ID: 35574418)
1. Tumor Suppressive Role of MUC6 in Wilms Tumor
Liu BH; Liu GB; Zhang BB; Shen J; Xie LL; Liu XQ; Yao W; Dong R; Bi YL; Dong KR
Front Oncol; 2022; 12():756117. PubMed ID: 35574418
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of Wilms' tumor gene 1 (WT1) in desmoid tumors.
Amini Nik S; Hohenstein P; Jadidizadeh A; Van Dam K; Bastidas A; Berry RL; Patek CE; Van der Schueren B; Cassiman JJ; Tejpar S
Int J Cancer; 2005 Mar; 114(2):202-8. PubMed ID: 15540161
[TBL] [Abstract][Full Text] [Related]
3. Activation of the Wnt/β-catenin pathway is common in wilms tumor, but rarely through β-catenin mutation and APC promoter methylation.
Schweigert A; Fischer C; Mayr D; von Schweinitz D; Kappler R; Hubertus J
Pediatr Surg Int; 2016 Dec; 32(12):1141-1146. PubMed ID: 27679509
[TBL] [Abstract][Full Text] [Related]
4. A Murine Model of K-RAS and β-Catenin Induced Renal Tumors Expresses High Levels of E2F1 and Resembles Human Wilms Tumor.
Yi Y; Polosukhina D; Love HD; Hembd A; Pickup M; Moses HL; Lovvorn HN; Zent R; Clark PE
J Urol; 2015 Dec; 194(6):1762-70. PubMed ID: 25934441
[TBL] [Abstract][Full Text] [Related]
5. [Effect of LncRNA HOTAIR on the proliferation, apoptosis and drug resistance of Wilms tumor cells through Wnt/β-catenin signaling pathway].
Yang LL; Cao GH; Liu YJ; Liu CH
Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):769-774. PubMed ID: 34289571
[No Abstract] [Full Text] [Related]
6. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
Maiti S; Alam R; Amos CI; Huff V
Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
[TBL] [Abstract][Full Text] [Related]
7. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA LINP1 induces tumorigenesis of Wilms' tumor by affecting Wnt/β-catenin signaling pathway.
Zhu KR; Sun QF; Zhang YQ
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5691-5698. PubMed ID: 31298321
[TBL] [Abstract][Full Text] [Related]
9. Target genes of the WNT/beta-catenin pathway in Wilms tumors.
Zirn B; Samans B; Wittmann S; Pietsch T; Leuschner I; Graf N; Gessler M
Genes Chromosomes Cancer; 2006 Jun; 45(6):565-74. PubMed ID: 16575872
[TBL] [Abstract][Full Text] [Related]
10. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors.
Ruteshouser EC; Robinson SM; Huff V
Genes Chromosomes Cancer; 2008 Jun; 47(6):461-70. PubMed ID: 18311776
[TBL] [Abstract][Full Text] [Related]
11. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
12. Nuclear accumulation of beta-catenin protein in Wilms' tumours.
Koesters R; Niggli F; von Knebel Doeberitz M; Stallmach T
J Pathol; 2003 Jan; 199(1):68-76. PubMed ID: 12474228
[TBL] [Abstract][Full Text] [Related]
13. Beta-catenin expression and mutation in adult and pediatric Wilms' tumors.
Su MC; Huang WC; Lien HC
APMIS; 2008 Sep; 116(9):771-8. PubMed ID: 19024596
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression profiles of mucin antigens in salivary gland mucoepidermoid carcinoma: MUC4- and MUC6-negative expression predicts a shortened survival in the early postoperative phase.
Honjo K; Hiraki T; Higashi M; Noguchi H; Nomoto M; Yoshimura T; Batra SK; Yonezawa S; Semba I; Nakamura N; Tanimoto A; Yamada S
Histol Histopathol; 2018 Feb; 33(2):201-213. PubMed ID: 28649694
[TBL] [Abstract][Full Text] [Related]
15. LncRNA MEG3 inhibits the growth, invasion and migration of Wilms' tumor via Wnt/β-catenin pathway.
Teng GY; Wang YJ; Geng M; Jiang ZP
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9899-9907. PubMed ID: 33090393
[TBL] [Abstract][Full Text] [Related]
16. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors.
Polosukhina D; Love HD; Correa H; Su Z; Dahlman KB; Pao W; Moses HL; Arteaga CL; Lovvorn HN; Zent R; Clark PE
Mol Oncol; 2017 Apr; 11(4):405-421. PubMed ID: 28188683
[TBL] [Abstract][Full Text] [Related]
17. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
18. Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies.
Fukuzawa R; Heathcott RW; More HE; Reeve AE
J Clin Pathol; 2007 Sep; 60(9):1013-6. PubMed ID: 17172473
[TBL] [Abstract][Full Text] [Related]
19. Expression of TCF3 in Wilms' tumor and its regulatory role in kidney tumor cell viability, migration and apoptosis
Zhou N; Yan B; Ma J; Jiang H; Li L; Tang H; Ji F; Yao Z
Mol Med Rep; 2021 Sep; 24(3):. PubMed ID: 34278464
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
